HER-2/neu Cancer Vaccines: Present Status and Future Prospects

摘要: Immunotherapeutic approaches to cancer should focus on novel undertakings that modulate immune responses by synergistic enhancement of anti-tumor immunological parameters. Cancer vaccines preferably be composed multiple defined tumor antigen specific B- and T-cell epitopes. The main this article is briefly review the present status Her-2/neu vaccine strategies describe innovative developed in my laboratory for a against HER-2/neu (ErbB-2) with emphasis humoral arm response. Elucidating underlining mechanisms effects elicited peptide self-protein requirement developing an immunotherapeutic strategy might effective human vaccines. Our approach entails identification biologically relevant epitopes, establishing vitro assays monitoring efficacy, devising engineer conformationally dependent sequences, highly immunogenic outbred population delivering immunogen/vaccine safe efficacious vehicle, utilizing transgenic animal models assessing development, challenge using transplantable tumors study efficacy constructs. We have multi-HER-2/neu B-cell epitope shown preclinical studies immunization combination two was more preventing mammary than single epitope. translated work clinic (OSU 0105) FDA approved, NCI sponsored “Phase 1 Active Immunotherapy trial Chimeric Multi-epitope based targeting HER-2 oncoprotein nor-MDP adjuvant patients metastatic and/or recurrent solid tumors” at James Hospital Ohio State University. correlation between overexpression up-regulation VEGF has been demonstrated breast patients. Thus, blocking angiogenesis attractive inhibit growth, invasion, metastasis. hypothesis anti-angiogenic therapy immunotherapy may important future goal. In review, I will discuss insights into our aid design next generation become integrated component prophylactic/preventive therapeutic approach.